Corona Virus
Stay Safe, FollowGuidance
Fetching Location Data…
Bob Mason
AstraZeneca covid

AstraZeneca and the University of Oxford

Following impressive phase 3 clinical trial results from Pfizer Inc. and Moderna Inc., AstraZeneca was in the spotlight today.

AstraZeneca and the University of Oxford released phase 3 clinical trial results today.

According to today’s press release:

  • Two dosing regimens were used in clinical trials carried out in the UK and Brazil.
  • One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose and then followed by a full dose at least one month apart.
  • The second dosing regimen (n=8,895) showed 62% efficacy when given as two full doses at least one month apart.
  • Combining both dosing regimens, the trials delivered an efficacy rate of 70%.
  • Importantly, there were no reported hospitalizations or severe cases of the disease.

While the clinical trial results were less impressive than those of Pfizer Inc. and Moderna Inc., AstraZeneca does have an edge.

The vaccine does not require similar refrigerated temperatures as those of Pfizer Inc. and Moderna Inc.

Combined with the group’s non-profit pledge, lower transportation costs will likely make the vaccine more accessible to developing economies.

As we had previously reported, AstraZeneca has already commenced the manufacturing of the vaccine in Australia. The decision to begin manufacturing before any clinical trials came in response to Pfizer Inc.’s first set of results.


The Latest COVID-19 Numbers

At the time of writing, the total number of COVID-19 cases worldwide stood at 59,078,540. The U.S alone accounted for 12,589,088 cases, with India accounting for 9,140,312.

Looking at the most affected EU member states, France, Spain, Italy, and Germany had a combined total of 6,070,406 cases. Back in mid-September, the 4 member states had a combined total of just 829,289 COVID-19 cases.

When you include the UK’s 1,512,045 total cases and consider the rest of the EU, the numbers aren’t too dissimilar to that of the U.S.

Both have faced similar issues as a result of allowing freedom of movement inter-state and across borders.

Containment measures are back in effect, however. Even the U.S administration has handed the reins to each state to manage the COVID-19 pandemic.

With winter now upon both the U.S and Europe, a vaccine cannot come fast enough.

Looking Ahead

For now, Pfizer Inc. and BioNTech look to remain ahead in the race to deliver a vaccine. The FDA is reportedly scheduled to review Pfizer Inc.’s EUA submission next month. By that time, Moderna Inc. will have also likely made its submission.

From the weekend, there were reports that Pfizer Inc. would be able to begin delivering the vaccine just days later.

While that is certainly positive news, a more worldwide inoculation would likely take longer, however.

That would mean that border restrictions globally would not come to an end as soon as the vaccine is available in the U.S.

While governments have placed their orders with the front runners, the rate of production will become a key consideration.

This may give AstraZeneca an edge going into the New Year. Much will depend on output numbers, however, and whether there are any manufacturing issues faced by the leading pharmas.

The race has, therefore, heated up and the likes of Johnson & Johnson, Medicago, Novavax, and Sanofi are facing a widening gap… Failure to deliver phase 3 clinical trials by the end of the year could leave the task of a global inoculation in the hands of the 3 front runners.

The Market Reaction

At the time of writing, AstraZeneca’s share price was down by 1.56% to £8,187.00. By contrast, however, riskier assets found support on expectations of an available vaccine by mid-December.

The weaker efficacy rates than those of Pfizer Inc. and Moderna Inc. contributed to the pullback.

While the efficacy rates are lower, AstraZeneca could enjoy a wider distribution network. As previously mentioned, the vaccine can be transported at higher temperatures that reduce transportation costs.

For investors, however, the non-profit pledge does offset the effect of the likely lower transportation costs on the bottom line.

With a number of major players trailing the front runners at present, any positive reports from the likes of Novavax would be well received.

Novavax is developing a vaccine that can be transported at temperatures of between 35F and 46F. This could become a deciding factor once the winter has passed. Phase 3 clinical trials are due out in the 1st quarter of next year.

Don't miss a thing!
Discover what's moving the markets. Sign up for a daily update delivered to your inbox

Trade With A Regulated Broker

  • Your capital is at risk
The content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your own due diligence checks, apply your own discretion and consult your competent advisors. The content of the website is not personally directed to you, and we does not take into account your financial situation or needs.The information contained in this website is not necessarily provided in real-time nor is it necessarily accurate. Prices provided herein may be provided by market makers and not by exchanges.Any trading or other financial decision you make shall be at your full responsibility, and you must not rely on any information provided through the website. FX Empire does not provide any warranty regarding any of the information contained in the website, and shall bear no responsibility for any trading losses you might incur as a result of using any information contained in the website.The website may include advertisements and other promotional contents, and FX Empire may receive compensation from third parties in connection with the content. FX Empire does not endorse any third party or recommends using any third party's services, and does not assume responsibility for your use of any such third party's website or services.FX Empire and its employees, officers, subsidiaries and associates, are not liable nor shall they be held liable for any loss or damage resulting from your use of the website or reliance on the information provided on this website.
This website includes information about cryptocurrencies, contracts for difference (CFDs) and other financial instruments, and about brokers, exchanges and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and come with a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money.FX Empire encourages you to perform your own research before making any investment decision, and to avoid investing in any financial instrument which you do not fully understand how it works and what are the risks involved.